Morphosys 新闻与活动
在场
Morphosys由Novartis所有。
是其中之一......
- Forbes Global 2000 (#100);
- Fortune 500 Europe (#62);
- Stoxx 600;
- Swiss market index;
- TOB Iconic 10,000.
Novartis 是一家在股票代码 NOVN (CH) 下上市的公司。
Novartis 在 37 个国家有直接业务。Novartis 拥有 74家子公司，其中包括 Alcon、Alcon ANZ 和 Alcon APAC。
他们在：
涉及Novartis的并购和融资。
- Novartis has announced the acquisition of Chinook Therapeutics (公布2023八月14号).
高管
查看带有其 29 名主要高管的组织结构图
Morphosys 搜索最多的简介
- Arkadius Pichota, Chief Executive Officer
- Barbara krebs-pohl, Chief Business Officer
- Lukas Gilgen, Chief Financial Officer
高管在Novartis变化
- Harry Kirsch, Member of the Executive Committee and Chief Financial Officer, 将于 20263月15 退休 (新闻发布的2025七月17号).
- Karen Hale 曾任 Chief Legal Officer and Member of the Executive Committee, 将于 20254月14 升职为 Chief Legal and Compliance Officer and Member of the Executive Committee (新闻发布的2025三月31号).
- Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, 将于 20254月14 退休 (新闻发布的2025三月31号).
创建提醒
跟踪 Morphosys 的高管变动
药店
Novartis 拥有 1,837 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- EQT has announced the acquisition of Adalvo (公布2025七月21号).
- ESSA Pharma and Xoma have announced they will merge (公布2025七月14号)..
- Pathos 凭借他的 365 百万美元筹款活动成为了独角兽。 (公布2025七月4号).
药店 行业的其他推荐联系人
消息
Morphosys 的最新新闻稿
- Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
- New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
- Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
- Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
- Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
- Novartis ranks first in 2024 Access to Medicine Index
- Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
- Official partner of the Eurovision Song Contest 2025
- Novartis Financial Results – Q3 2024
- Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
- View more press releases Close
